The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.

Abstract

A double-blind placebo-controlled prospective trial assessed the effect of a slow release formulation of bezafibrate (Bezalip Mono) on lipids, glucose homeostasis, platelet function and plasma fibrinogen in non-insulin dependent (type II) diabetics. Twenty-four patients completed the trial. There was a significant improvement in the cholesterol and… (More)

Topics

Cite this paper

@article{Mathur1990TheEO, title={The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.}, author={Sheenu Mathur and Mar{\'i}a del Roc{\'i}o Aguilar Barradas and Dimitri P. Mikhailidis and Paresh Dandona}, journal={Diabetes research}, year={1990}, volume={14 3}, pages={133-8} }